Phosphate Binder (Unspecified)

Verify with FDA CVM →

33 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
33
Total Reports
5
Deaths Reported
1520.0%
Death Rate

Active Ingredients

Phosphate Binder (Unspecified)

Administration Routes

UnknownOralSubcutaneous

Species Affected

Cat 29
Dog 4

Most Affected Breeds

Domestic Shorthair 17
Cat (unknown) 6
Domestic Longhair 2
Domestic Mediumhair 2
Chihuahua 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Shih Tzu 1
Himalayan 1
Persian 1
Dog (unknown) 1

Most Reported Reactions

Lack of efficacy - NOS 13
Weight loss 7
Decreased haematocrit 6
Decreased appetite 4
Elevated creatinine 4
Lethargy (see also Central nervous system depression in Neurological) 3
Elevated symmetrical dimethylarginine (SDMA) 3
Hyperphosphataemia 3
Diarrhoea 3
Death by euthanasia 3
Dehydration 3
Pica NOS 2

Outcome Breakdown

Outcome Unknown
14 (42.4%)
Ongoing
12 (36.4%)
Euthanized
3 (9.1%)
Recovered/Normal
2 (6.1%)
Died
2 (6.1%)

Data Summary

Metric Value
Total adverse event reports 33
Reports involving death 5
Case-fatality rate (reported events) 1520.0%
Distinct species in reports 2
Distinct breeds in reports 10
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Phosphate Binder (Unspecified) Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 33 adverse event reports referencing Phosphate Binder (Unspecified), including 5 reports in which the animal died — a 1520.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Phosphate Binder (Unspecified). Reported administration routes include Unknown, Oral, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Phosphate Binder (Unspecified) reports are Cat (29 reports), Dog (4 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (17), Cat (unknown) (6), Domestic Longhair (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Phosphate Binder (Unspecified) are Lack of efficacy - NOS (13), Weight loss (7), Decreased haematocrit (6), Decreased appetite (4). Of the 33 reports with a coded outcome, Outcome Unknown is the leading category at 42.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Phosphate Binder (Unspecified).

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial